Skip to main content
Bruce Yacyshyn, MD, Gastroenterology, Cincinnati, OH


Gastroenterology Cincinnati, OH

Inflammatory Bowel Disease, Clinical Pharmacology, Clinical Informatics

Professor of Pharmacology and systems physiology, University of Cincinnati School of Medicine. Consultant, Tower Hill Consulting LLC. Co-Founder, Musidora Biotechnology

Dr. Yacyshyn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Yacyshyn's full profile

Already have an account?


  • Dr. Bruce Yacyshyn is a specialist in Gastroenterology. He received his medical degree from University of Alberta Faculty of Medicine and has been in practice 40 years. He specializes in inflammatory bowel disease (IBD) as well as general gastroenterology, translational and clinical GI research. His "firsts" includes adhesion molecule therapeutics for IBD (ACT-1/Vedolizumab), Inflammatory molecules in the GI tract (HIF), lead investigator for first human systemic use of a systemic antisense molecule in IBD (alicaforsen), and predictive proteomic, development of centrally reviewed scoring system for ulcerative colitis (UCEIS) and the involvement ofpermeability alterations as a risk for IBD development. He has designed and executed numerous clinical research projects both in industry and academics. He is a Professor in Pharmacology and systems physiology (voluntary track) at the University of Cincinnati and a co-founder of Musidora Biotechnology. He is a consultant to Biotechnology and Pharma industry through his role as a consultant at Tower Hill Consulting , LLC.

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Gastroenterology, 1986 - 1989
  • University of Alberta
    University of AlbertaClass of 1982
  • University of Alberta
    University of AlbertaBSc, 1980

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 1986 - 2025
  • OH State Medical License
    OH State Medical License 2001 - 2025
  • IN State Medical License
    IN State Medical License 2008 - 2025
  • KY State Medical License
    KY State Medical License 2014 - 2025
  • American Board of Internal Medicine Internal Medicine
  • Royal College of Physicians of CanadaGastroenterology
  • Royal College of physicians of CanadaInternal Medicine

Awards, Honors, & Recognition

  • Uniting to Care and Cure award 2019 Crohns and Colitis Foundation, 2019
  • Top Doc Gastroenterology, Crohn's Cincinnati Magazine, 2014
  • Patient Experience Award UCMC Hospital, 2016
  • Join now to see all

Clinical Trials

Publications & Presentations


Journal Articles

  • Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection  
    Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves ..., N Engl J Med, 1/1/2017
  • Mo1670 Role for Differences in TLR Expression in the Clearance of Clostridium difficile Infections  
    Singh AD, Engevik KA, Yacyshyn MB, Yacyshyn BR., Gastroenterology, 1/1/2016
  • Epithelial Regeneration After Gastric Ulceration Causes Prolonged Cell-Type Alterations  
    Aihara E, Matthis AL, Karns RA, Engevik KA, Jiang P, Wang J, Yacyshyn BR, Montrose MH., Cell Mol Gastroenterol Hepatol., 1/1/2016
  • Join now to see all

Books/Book Chapters

  • Join now to see all


  • Clostridium difficile Toxins A and B Decrease SLC26A3 Protein Expression in Human Intestinal Epithelial Cells.
    Coffing H, Priyamvada S, Natarajan Anbazhagan A, Salibay C, Engevik M, Versalovic J, Yacyshyn MB, Yacyshyn B, Tyagi S, Saksena S, Gill R, Alrefai W, Dudeja P., American Journal of Physiology-Gastrointestinal and Liver Physiology, 1/1/2018
  • Bezlotoxumab for prevention of recurrent C. difficile infection in patients at increased risk for recurrence
    Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, Yacyshyn B, Kao D, Eves K, Ellison MC, Hanson ME, Guris D, Dorr MB., Clin Infect Dis., 1/1/2018
  • Upadacitinib phase 2 study Celest.
    Yacyshyn BR, United European Gastroenterology Week, 1/1/2018
  • Join now to see all


  • Pathogenesis and Immunology of recurrent C. difficile infection 
    St. Vincent�s Hospital, Melbourne, Australia, 2015; Alfred Hospital, Monash University, Melbourne, A - 1/1/2015
  • Treating Inflammatory Disease with Biosimilars: What Every GI Specialist Should Know 
    Honolulu, HI - 1/1/2015
  • C. difficile for the Clinician 
  • Join now to see all


  • Clostridium difficile Toxins A and B Decrease SLC26A3 Protein Expression in Human Intestinal Epithelial Cells. 
    Coffing H, Priyamvada S, Natarajan Anbazhagan A, Salibay C, Engevik M, Versalovic J, Yacyshyn MB, Yacyshyn B, Tyagi S, Saksena S, Gill R, Alrefai W, Dudeja P
  • Special Report: Management of Global Enteric Infections 
    Yacyshyn, BR., Gastroenterology and Endoscopy News
  • Information on medications commonly used for people suffering from Crohn�s disease or ulcerative colitis. 
    Fedorak RN, Fisher D, Yacyshyn BR, Thomson ABR
  • Join now to see all

Authored Content

  • Luminal and Liver Highlights from DDW 2022May 2022
  • What I Learned at ACG: Check Labs Before Doing Anything Based on Questionable TestingNovember 2019
  • IBD Updates and Posters Galore at ACGNovember 2019
  • IBD content and posters galore at ACG 2019November 2019
  • Join now to see all

Press Mentions

  • Will Opioids Be Replaced Anytime Soon?
    Will Opioids Be Replaced Anytime Soon?October 7th, 2018
  • Olorinab Eases Abdominal Pain Associated with Crohn’s Disease in Phase 2a Trial
    Olorinab Eases Abdominal Pain Associated with Crohn’s Disease in Phase 2a TrialSeptember 26th, 2018


  • IRB member, Robley Rex Louisville VAMC 2020 - 2021

Professional Memberships

Industry Relationships

  • Clinical/Medical Advisor, ClostraBio Inc.Clinical/Medical Advisor2023 - Present
  • Vice President, Medpace, IncProtocol development, medical monitoring, FDA industry representation, bid preparation and presentation, Drug development team (CinRx and Cindome).2021 - 2023
  • Clinical/Scientific advisor, Aerpio Inc.Lead Scientific advisor for GB-004 (formerly AKB 4924) for IBD therapy. Part of team responsible for preclinical and early phase clinical development for this compound.2017 - 2021
  • Scientific advisor, Isodiagnostica IncResearch/Clinical Advisor2018 - 2020
  • North America Clinical Development Medical Director, Procter and Gamble Pharmaceuticals, Inc.Lead clinical development of Asacol HD, (including design of Ascend 3 clinical trials, FDA industry representation). GI category lead including ATI-7505, biomarker development, Align clinical development, Prilosec lead. Advisor to Futureworks (lactoferrin) and IAMS. Member, Licensing & Acquisition.2005 - 2008
  • Clinical Advisor, Ionis (Isis) pharmaceuticalsLead investigator, Alicaforsen clinical research in IBD therapy.1998 - 2005
  • Clinical/Scientific advisor, ICOSIBD research/clinical research1998 - 2000